Santen Pharmaceutical has filed a patent for a drug formulation containing sepetaprost as an active ingredient. The formulation aims to treat or prevent glaucoma or ocular hypertension in patients who do not respond well to other therapeutic agents. The drug is expected to have a significant intraocular pressure-lowering effect in patients with drug-refractory glaucoma or ocular hypertension. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230285411A1) describes a pharmaceutical formulation for treating or preventing glaucoma or ocular hypertension. The formulation contains sepetaprost as an active ingredient and is intended for patients who have not responded adequately to other therapeutic agents for these conditions. Glaucoma and ocular hypertension are conditions characterized by high intraocular pressure, and the formulation aims to further lower this pressure when other treatments have been ineffective.
The patent claims specify that the other therapeutic agents for glaucoma or ocular hypertension may include prostaglandin F2a derivatives or latanoprost. The content of sepetaprost in the pharmaceutical formulation ranges from 0.0001% to 0.05% (w/v), with specific concentrations of 0.001% to 0.005% (w/v) or 0.002% (w/v) mentioned. The formulation is administered as an eye drop.
In addition to the formulation, the patent also describes methods of treating or preventing glaucoma or ocular hypertension using sepetaprost. These methods involve administering the pharmaceutical formulation to patients who have not responded adequately to other therapeutic agents. The goal of treatment or prevention is to further lower intraocular pressure following previous treatment with other agents.
The patent also mentions a method that includes a step-wise approach to treatment or prevention. This method involves initially administering a therapeutic agent other than sepetaprost, determining if it has an inadequate effect, and then proceeding to administer the sepetaprost-containing formulation if needed.
Overall, this patent presents a pharmaceutical formulation and methods for treating or preventing glaucoma or ocular hypertension using sepetaprost as an active ingredient. The formulation is intended for patients who have not responded adequately to other therapeutic agents, and the goal is to further lower intraocular pressure. The patent provides specific concentrations of sepetaprost and describes the administration of the formulation as an eye drop.
To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
